Lifecore Biomedical director granted 25,907 RSUs

Lifecore Biomedical director Paul Harold Johnson received an equity award of 25,907 restricted stock units that convert into common stock on a 1-for-1 basis.

Rhea-AI Filing Summary

Lifecore Biomedical director Paul Harold Johnson received an equity award of 25,907 restricted stock units that convert into common stock on a 1-for-1 basis. The award is recorded at a price of $0.00 per share as a grant/award acquisition and is held directly.

The units vest on the earlier of June 4, 2027 or the date of the company’s annual meeting of stockholders first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026. Following this grant, Johnson holds 69,967 shares of common stock.

Insider Trade Summary

Grant/Award: 25,907 shares

Grant/Award 1 txn

Insider Johnson Paul Harold

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,907	$0.00	$0.00

Holdings After Transaction: Common Stock — 69,967 shares (Direct)

Footnotes (2)

1. F1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
2. F2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Key Figures

RSU grant: 25,907 units Grant price: $0.00 per share Post-grant holdings: 69,967 shares +2 more

5 metrics

RSU grant 25,907 units Restricted stock units granted to director on June 4, 2026

Grant price $0.00 per share Recorded value for the RSU award

Post-grant holdings 69,967 shares Total common stock held after the transaction

Vesting date June 4, 2027 Latest possible vesting date, unless 2027 annual meeting occurs earlier

50-week condition 50 weeks Annual meeting must be at least 50 weeks after June 4, 2026

Key Terms

restricted stock units, 1 for 1 basis, vests, annual meeting of stockholders, +1 more

5 terms

restricted stock units financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

1 for 1 basis financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

vests financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

annual meeting of stockholders financial

"the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lifecore Biomedical (LFCR) director Paul Harold Johnson report in this Form 4?

Paul Harold Johnson reported receiving 25,907 restricted stock units as an equity award. These units convert into Lifecore Biomedical common stock on a 1-for-1 basis, increasing his holdings to 69,967 shares after the grant.

How many restricted stock units were granted to the Lifecore Biomedical (LFCR) director?

The director was granted 25,907 restricted stock units. Each unit represents the right to receive one share of Lifecore Biomedical common stock, subject to the specified vesting schedule described in the filing’s footnotes.

When do Paul Harold Johnson’s Lifecore Biomedical (LFCR) restricted stock units vest?

The restricted stock units vest on the earlier of June 4, 2027 or the date of Lifecore Biomedical’s annual stockholders meeting first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026.

What is Paul Harold Johnson’s Lifecore Biomedical (LFCR) share ownership after this Form 4 transaction?

After the reported grant, Paul Harold Johnson holds 69,967 shares of Lifecore Biomedical common stock. This total reflects his direct ownership position following the award of 25,907 restricted stock units.

Is the Lifecore Biomedical (LFCR) Form 4 transaction an open-market purchase or a compensation grant?

The transaction is a compensation-related grant. It is coded as a grant, award, or other acquisition (Code A) with a $0.00 per-share value, indicating an equity award rather than an open-market stock purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson Paul Harold

(Last) (First) (Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA MINNESOTA 55318

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		25,907	A	(1)(2)	69,967	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Remarks:

	/s/ Courtney Schuler, Attorney-In-Fact for Paul H Johnson	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)